Literature DB >> 21358463

Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-up.

André M Coutinho1, Rufino M Silva, Sandrina G Nunes, Maria L Cachulo, João P Figueira, Joaquim N Murta.   

Abstract

PURPOSE: To evaluate the long-term safety and efficacy of photodynamic therapy in the treatment of choroidal neovascularization associated with pathologic myopia.
METHODS: Five-year retrospective study of 43 consecutive eyes of 36 patients with juxtafoveal or subfoveal choroidal neovascularization and pathologic myopia treated with photodynamic therapy.
RESULTS: Mean best-corrected visual acuity changed from 20/125 +1 letter (0.78 logarithm of the minimum angle of resolution) at baseline to 20/100 (0.70 logarithm of the minimum angle of resolution) at 5 years (P = 0.122). Final best-corrected visual acuity improved in 53.5% of the eyes, remained stable in 11.6%, and decreased in 34.9%. A visual acuity gain of ≥3 lines occurred in 32.6% of the eyes, and a visual acuity decrease of ≥3 lines was registered in 20.9% of the cases at 5 years. Only patient's age and initial visual acuity showed to have a significant predictive value for the final visual acuity outcome (P = 0.024 and P = 0.002, respectively).
CONCLUSION: Photodynamic therapy with verteporfin may increase the chance of stabilizing and improving vision in patients with choroidal neovascularization from pathologic myopia at 5 years. Better results were found in younger patients (<55 years).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21358463     DOI: 10.1097/IAE.0b013e3181ff9546

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  5 in total

1.  Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.

Authors:  T Y Y Lai; F O J Luk; G K Y Lee; D S C Lam
Journal:  Eye (Lond)       Date:  2012-05-18       Impact factor: 3.775

2.  Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization.

Authors:  C S Tan; M C Chew; T H Lim
Journal:  Eye (Lond)       Date:  2013-09-20       Impact factor: 3.775

Review 3.  Current and emerging treatment options for myopic choroidal neovascularization.

Authors:  Leila El Matri; Ahmed Chebil; Fedra Kort
Journal:  Clin Ophthalmol       Date:  2015-04-24

4.  A systematic review of clinical practice guidelines for myopic macular degeneration.

Authors:  Yanxian Chen; Xiaotong Han; Iris Gordon; Sare Safi; Gareth Lingham; Jennifer Evans; Jinying Li; Mingguang He; Stuart Keel
Journal:  J Glob Health       Date:  2022-03-26       Impact factor: 4.413

Review 5.  Myopic choroidal neovascularisation: current concepts and update on clinical management.

Authors:  Tien Y Wong; Kyoko Ohno-Matsui; Nicolas Leveziel; Frank G Holz; Timothy Y Lai; Hyeong Gon Yu; Paolo Lanzetta; Youxin Chen; Adnan Tufail
Journal:  Br J Ophthalmol       Date:  2014-07-01       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.